Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Acta Medica Iranica. 2013; 51 (8): 513-519
Dans Anglais | IMEMR | ID: emr-142878

Résumé

Cyclin E, HER-2 and p53, are considered as major prognostic markers in breast cancer. As they are related in patho-clinical level, we aimed to check if they have any direct interaction on expression of each other. To study the effect of cyclin E on HER-2 expression, cell lines stably overexpressing cyclin E or its low molecular weight [LMW] isoforms were generated. To understand the results of p53 silencing either alone or in combination with cyclin E overexpression, we created three different p53 stably knocked down cell lines. Protein expression was analyzed by western blot, HER-2 expression in the established cell lines were determined using SYBR green real time PCR and data analyzed by REST software. Results indicate that HER-2 expression is only downregulated following p53 silencing and none of cyclin E isoforms can alter its expression. The presence of cyclin E isoforms in p53 silenced clones also does not altered HER-2 expression. Given the fact that p53 degradation is increased by HER-2 overexpression, these data can draw a regulatory loop in which a non-mutated functional p53 and HER-2 can bidirectionally regulate the expression of these two genes. This study improves our understandings of these pathways and these proteins can be introduced either as a marker or as a target in cancer treatment.


Sujets)
Humains , Femelle , Récepteur ErbB-2/génétique , Récepteur ErbB-2/métabolisme , Cycline E/physiologie , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Régulation de l'expression des gènes tumoraux , Cellules MCF-7 , Réaction de polymérisation en chaîne , Amorces ADN
SÉLECTION CITATIONS
Détails de la recherche